دورية أكاديمية
أعرض في EDS

Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database.

التفاصيل البيبلوغرافية
العنوان: Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database.
المؤلفون: Lee JW; Department of Obstetrics and Gynecology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si 15355, Gyeonggi-do, Republic of Korea., Ouh YT; Department of Obstetrics and Gynecology, School of Medicine, Kangwon National University, 156, Baengnyeong-ro, Chuncheon-si 24289, Gangwon-do, Republic of Korea., Chang HK; Department of Obstetrics and Gynecology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si 15355, Gyeonggi-do, Republic of Korea., Min KJ; Department of Obstetrics and Gynecology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si 15355, Gyeonggi-do, Republic of Korea., Lee S; Department of Obstetrics and Gynecology, Korea University Anam Hospital, 73, Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea., Hong JH; Department of Obstetrics and Gynecology, Korea University Guro Hospital, 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea., Song JY; Department of Obstetrics and Gynecology, Korea University Anam Hospital, 73, Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea., Lee JK; Department of Obstetrics and Gynecology, Korea University Guro Hospital, 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea., Lee NW; Department of Obstetrics and Gynecology, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si 15355, Gyeonggi-do, Republic of Korea.
المصدر: Journal of clinical medicine [J Clin Med] 2023 Feb 02; Vol. 12 (3). Date of Electronic Publication: 2023 Feb 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2012]-
مستخلص: Carcinosarcomas (malignant mixed Mullerian tumors) of a female genital organ are rare tumors associated with a poor survival. The purpose of this study was to identify site-specific differences in the incidence and prognosis in carcinosarcomas originating in the uterus, cervix, or ovary. The data of patients with gynecologic carcinosarcomas were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2016. The characteristics of gynecologic carcinosarcomas were compared using Pearson X2 and Fisher's exact tests. Kaplan-Meier models were used for cause-specific survival (CSS) analysis. The cohort included 7086 females, including 5731 cases of uterine carcinosarcoma, 161 cervical carcinosarcomas, and 1193 ovarian carcinosarcomas. The age-adjusted incidence rates of uterine, cervical, and ovarian carcinosarcoma were 3.9, 0.1, and 0.6 per 1,000,000, respectively. In the distribution of carcinosarcoma incidence by race, compared with the uterus or cervix, those originating from the ovary were unequally distributed in Caucasians (84.4% versus 69.6%, 67.7%; p < 0.001). The incidence of uterine carcinosarcoma steadily increased over time, from 2.2 in 2000 to 5.5 in 2016 (per 1,000,000), while cervical or ovarian carcinosarcoma showed no significant difference in incidence. The five-year CSS rates based on the site of origin (uterus, cervix, and ovary) were 39.9%, 33.1%, and 25.8%, respectively. The incidence rates of gynecologic carcinosarcoma, especially uterine carcinosarcoma, are gradually increasing. Although uterine carcinosarcoma is associated with a higher incidence than the others, it has a better prognosis compared with ovarian and cervical carcinosarcoma. The survival rates were worst in ovarian carcinosarcoma.
References: Gynecol Oncol. 2007 Nov;107(2):177-85. (PMID: 17822748)
Scott Med J. 2013 May;58(2):88-94. (PMID: 23728753)
Crit Rev Oncol Hematol. 2019 Feb;134:46-55. (PMID: 30771873)
Cancer. 2003 Jul 1;98(1):176-86. (PMID: 12833470)
Gynecol Oncol. 1997 Apr;65(1):158-63. (PMID: 9103406)
Clin Transl Oncol. 2011 May;13(5):307-14. (PMID: 21596658)
Gynecol Oncol. 2016 Aug;142(2):248-54. (PMID: 27321238)
Gynecol Oncol. 2014 May;133(2):238-41. (PMID: 24613675)
Clin Med Insights Oncol. 2021 Dec 8;15:11795549211056273. (PMID: 35153524)
Am J Surg Pathol. 2001 Mar;25(3):338-47. (PMID: 11224604)
Gynecol Oncol. 2014 Jun;133(3):401-4. (PMID: 24878391)
Semin Cancer Biol. 2020 Apr;61:110-120. (PMID: 31622660)
Eur J Obstet Gynecol Reprod Biol. 2021 Nov;266:106-110. (PMID: 34624737)
Am J Clin Oncol. 2018 Aug;41(8):784-791. (PMID: 28121642)
Int J Clin Oncol. 2018 Feb;23(1):114-120. (PMID: 28836024)
Crit Rev Oncol Hematol. 2021 Jul;163:103369. (PMID: 34051304)
Gynecol Oncol. 2015 Jun;137(3):581-8. (PMID: 25805398)
J Obstet Gynaecol Can. 2021 Jan;43(1):34-42. (PMID: 33041218)
Int J Gynecol Cancer. 2017 Nov;27(9):1957-1969. (PMID: 28708788)
Gynecol Oncol. 2020 Apr;157(1):67-77. (PMID: 32029291)
N Engl J Med. 2020 Oct 1;383(14):1340-1348. (PMID: 32997908)
Int J Gynecol Cancer. 2014 Mar;24(3):506-12. (PMID: 24557435)
J Gynecol Oncol. 2018 Mar;29(2):e22. (PMID: 29400015)
J Gynecol Oncol. 2017 Mar;28(2):e32. (PMID: 28198168)
Oncol Res Treat. 2018;41(11):675-679. (PMID: 30317231)
فهرسة مساهمة: Keywords: SEER; carcinosarcoma; cervical; ovarian; prognosis; survival; trends; uterine
تواريخ الأحداث: Date Created: 20230211 Latest Revision: 20230213
رمز التحديث: 20230213
مُعرف محوري في PubMed: PMC9917500
DOI: 10.3390/jcm12031188
PMID: 36769835
قاعدة البيانات: MEDLINE
الوصف
تدمد:2077-0383
DOI:10.3390/jcm12031188